NCT03465501 (BOOST-CA) is a clinical trial of Brachytherapy in Anal Canal Cancer, sponsored by Institut Paoli-Calmettes.

Who is sponsoring NCT03465501?

NCT03465501 is sponsored by Institut Paoli-Calmettes.

What drugs are being tested in NCT03465501?

Interventions in NCT03465501: Brachytherapy.

What condition does NCT03465501 study?

NCT03465501 studies Anal Canal Cancer.

Is NCT03465501 still recruiting?

NCT03465501 is currently completed. Last updated 14 March 2018.

Last reviewed 2018-03-14 · How we verify

NCT03465501: BOOST-CA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates

Completed Last updated 14 March 2018

What this trial tests

trial testing Brachytherapy in Anal Canal Cancer in 89 participants. Completed in 28 July 2016.

Timeline

17 August 2007

Primary endpoint
28 July 2016

28 July 2016

Quick facts

Lead sponsor	Institut Paoli-Calmettes
Status	Completed
Study type	OBSERVATIONAL
Enrollment	89
Start date	17 August 2007
Primary completion	28 July 2016
Estimated completion	28 July 2016
Sites	1 location across France

Drugs / interventions tested

Brachytherapy — full drug profile →

Conditions studied

Anal Canal Cancer — all drugs for Anal Canal Cancer →

Sponsor

Institut Paoli-Calmettes — full company profile →

Who can join

18 and older, any sex, with Anal Canal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparative retrospective study of two anal canal brachytherapy techniques aimed at boosting \[low dose rate (LDR) and high dose rate (HDR)\]

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Brachytherapy

Trials testing the same drug.

NCT07061977 — Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C · Phase 3 · recruiting
NCT07182279 — Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer · Phase 1, PHASE2 · recruiting
NCT06543576 — External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cer · Phase 1, PHASE2 · recruiting
NCT06333821 — A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma · Phase 3 · not yet recruiting
NCT06129851 — Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer · Phase 2 · not yet recruiting

Other recruiting trials for Anal Canal Cancer

Currently open trials in the same condition.

NCT03403465 — Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers · Phase 2 · active not recruiting

Other Institut Paoli-Calmettes trials

Trials by the same sponsor.

NCT07461142 — Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers · NA · not yet recruiting
NCT06557421 — De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients · Phase 2 · recruiting
NCT06046794 — Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · NA · recruiting
NCT06055621 — Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE · Phase 2 · recruiting
NCT05986071 — I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03465501 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Paoli-Calmettes
Last refreshed: 14 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03465501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing